What the trial was testing
The ILLUMINATE-A enrolled 39 patients with kidney disease. The study was sponsored by Alnylam Pharmaceuticals and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Lumasiran reduced urinary oxalate by 65%, with 84% of patients reaching normal or near-normal levels after 6 months.
The New England journal of medicine · 2021 · NCT03681184
These findings — that reached normal or near-normal urinary oxalate levels after 6 months of treatment — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 39 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with kidney disease, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Lumasiran is FDA-approved for primary hyperoxaluria type 1. It's given as an injection under the skin and works by reducing the liver's production of oxalate, helping prevent kidney damage. If you have PH1, ask your doctor if lumasiran is right for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open kidney disease trials
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.